S ickle cell disease (SCD), caused by a β-globin gene mutation, is characterized by chronic systemic complications because of vaso-occlusive episodes and hemolysis. 1 Although first described >60 years ago, SCD continues to be associated with poor outcomes with median age at death of 45 years 1,2 and remains a dramatic example of health disparity when compared with other populations with chronic illness. Cardiovascular manifestations, including left ventricular (LV) diastolic dysfunction and pulmonary hypertension, are independently associated with mortality. 3, 4 Within the past decade, pulmonary hypertension in SCD has been well characterized, 3,5,6 whereas little progress has been made on understanding the presence of diastolic dysfunction.
aim of this study is 2-fold: (1) to characterize systolic and diastolic LV function in adults with SCD and (2) to determine the pathogenesis of diastolic dysfunction in patients with SCD using a combination of noninvasive cardiovascular testing modalities.
Methods

Subjects
Subjects from the University of Chicago were recruited from adult SCD outpatient programs, providing written consent to participate in this study with the approval of the institutional human subjects review board. Details of trial registration are provided at the website http://clinicaltrials.gov/ct2/show/NCT01044901. A total of 38 clinically stable black patients with SCD (including individuals with hemoglobin SS, SC, and β-thalassemia demonstrated by high-performance liquid chromatographic separation or gel electrophoresis) and 13 healthy control subjects were enrolled in this study; controls were frequency matched to patients with SCD on age, sex, and race. A multimodality noninvasive cardiovascular testing strategy, including transthoracic echocardiography (TTE), cardiovascular magnetic resonance (CMR), and applanation tonometry, was performed prospectively on the same day. Subjects were excluded only if they were clinically unstable, defined as having vaso-occlusive crisis, acute chest syndrome, or unscheduled blood transfusions within 3 weeks of the study. If subjects were unable to complete portions of the tonometry or the CMR exam (mostly because of either standard contraindications or inability to obtain appropriate intravenous access), subjects remained participants in the study, and their portion of completed exams was still included for appropriate analyses. Subjects were followed up for vital status assessment for ≤3 years with phone calls and annual reviews of electronic medical records. History of transfusion burden and sickle crisis was obtained by a combination of patient survey and review of the University of Chicago electronic medical records.
Transthoracic Echocardiography
TTE was performed within 4 hours of the CMR. The images were obtained using an S5 probe connected to an iE33 ultrasound machine (Philips Healthcare, Andover, MA). Digital cine loops were acquired by a single highly experienced sonographer and subsequently reviewed off line. Diastolic dysfunction was assessed using the American Society of Echocardiography guidelines. 8 Diastolic function was determined to be normal by tissue Doppler imaging when both peak septal e′ (mitral annulus) velocity was >8 cm/s and peak lateral e′ velocity was >10 cm/s. Diastolic dysfunction was graded either I (mild) to II (moderate) or III (severe) using tissue Doppler imaging and pulsed Doppler peak E and A velocities, E/A ratio, and deceleration time. 9 The peak e′ velocity was used to calculate a septal and lateral E/e′ ratio. Mild diastolic dysfunction was defined as an E/A ratio of <1.0. Moderate diastolic dysfunction was defined as an E/A ratio of ≥1.0, and an E/e′ ratio of >12. Severe diastolic dysfunction was defined as an E/A ratio ≥1.0, deceleration time <140 ms, and E/e′ >12. 8
CMR Acquisition
CMR images were acquired using a 1.5-T scanner (Achieva, Philips, Best, The Netherlands) using a 5-element phased array cardiac coil. The CMR study included assessments of cardiac function, microvascular function, myocardial fibrosis, and myocardial and hepatic iron. Before contrast administration, T2* imaging was performed in 1 midventricular short-axis slice and 1 coronal slice through the liver to assess myocardial and hepatic iron content using a single breath-hold, black blood multiecho (2.3-14 ms) cardiac-triggered spin echo pulse. Next, resting first pass myocardial perfusion images were acquired in 3 short-axis slices during infusion of gadolinium-diethylenetriamine pentaacetic acid-bismethylamide (Omniscan, 0.025 mmol/kg at 4 mL/s IV) for ≈60 consecutive heartbeats using a hybrid gradient echo/echo planar imaging sequence (voxel size, ≈2.5×2.5mm; slice thickness, 10 mm; flip angle, 20°; repetition time, 5.9 ms; echo time [TE], 2.5 ms; Echo Planar Imaging factor, 5; delay time, 80 ms; and sensitivity encoding (SENSE) factor, 1.3). Then, retrospectively gated cine images were obtained using steady-state-free precession (repetition time, 2.9 ms; TE, 1.5 ms; flip angle, 60°; and temporal resolution, <40 ms). Standard long-axis views were obtained, including 4-chamber, 2-chamber, and 3-chamber images. In addition, 1 series of short-axis slices (8-mm thickness, 2-mm gap) covering the entire heart was acquired. After the cine acquisition was completed, regadenoson (Lexiscan, 0.4 mg IV; Astellas Pharma, Deerfield, IL) was administered to induce hyperemia, and stress myocardial perfusion images were obtained 60 to 90 seconds later during infusion of gadolinium-diethylenetriamine pentaacetic acid-bismethylamide (0.025 mmol/kg at 4 mL/s IV). Hyperemia was reversed with intravenous aminophylline 75 to 125 mg. Late gadolinium enhancement (LGE) images of the above-described short-and long-axis views were obtained 10 minutes after the administration of another 0.15 mmol/kg of gadolinium-diethylenetriamine pentaacetic acid-bismethylamide using a T1-weighted gradient echo pulse sequence with a phase-sensitive inversion recovery reconstruction (repetition time, 4.5 ms; TE, 2.2 ms; inversion time, 250-300 ms; flip angle, 30°; flip angle, 5°; voxel size, 2×2×10 mm; SENSE, factor 2). An inversion time typically between 250 and 300 ms was used to achieve nulling of normal myocardium. Heart rate, blood pressure, and symptoms were monitored throughout the entire examination.
CMR Image Analysis
Images were analyzed using commercial software (Philips ViewForum, Best, Netherlands). (1) Cardiac functional assessment: short-axis slices were used to measure maximal left and right atrial volumes, LV and right ventricular end-diastolic and end-systolic volumes, mass, and ejection fraction (EF) by the Simpson method of disks. 10 All volumes and masses were indexed for body surface area.
(2) Microvascular function assessment: myocardial perfusion reserve index was determined using the stress and rest myocardial perfusion images. Epicardial and endocardial borders of mid-LV slice were manually traced for each frame, myocardial segmentation was applied, and time-signal intensity curves were generated for each myocardial segment and the LV cavity during resting conditions and stress conditions. The maximum myocardial upslopes were normalized to the LV cavity upslope and averaged for all myocardial segments. Myocardial perfusion reserve index was calculated as the upslope ratio of stress to rest. (3) Myocardial fibrosis assessment:
LGE was considered to be present in the LV myocardium if the signal intensity was >5 SDs more than the mean signal intensity of a remote normal segment and if it was seen in 2 adjacent slices or transverse imaging planes. (4) Hepatic and myocardial iron assessment: tissue T2* signal intensity was measured in a homogenous region of interest in the LV septum and liver at 2 separate TEs. T2*=−∆TE/ln (SI TE2 /SI TE1 ), where ∆TE represents the time difference between the 2 echo times and SI TE1 and SI TE2 represent signal intensity at these echo times. Myocardial and hepatic T2* were considered abnormal if <20 and <18 ms, respectively.
Applanation Tonometry
Pulse wave analysis of the radial artery was performed using applanation tonometry (SphygmoCoR, AtCor Medical). Three separate measurements were obtained to determine the augmentation pressure and index (AI), a surrogate of aortic stiffness. 11 Data sets were only accepted if all quality control indices (average pulse height, pulse height variation, diastolic variation, and shape deviation) were met and the operator index was >90%.
Statistical Analysis
Continuous measurements are reported as either mean±SD or median with interquartile range. Comparisons of continuous variables with skewed distributions in patients with SCD versus control patients, as well as in subgroup analyses with LGE and diastolic dysfunction, were made using the Wilcoxon rank-sum test. Normally distributed data were compared using t test. Fisher test was used for categorical data. Associations between continuous variables were assessed using the Spearman rank correlation coefficient. Analyses were performed in Prism 5.0 (Graphpad, La Jolla, CA). Table 1 displays the clinical characteristics of the SCD cohort. Briefly, all patients were blacks. The majority of the subjects carried a hemoglobin SS genotype (79%), whereas the remainder were hemoglobin SC and S/B-thalassemia. Almost all subjects had near normal creatinine values and clearance (not shown). As would be expected, increasing age significantly correlated with diastolic blood pressure (r=0.47; P=0.004) and creatinine levels (r=0.37; P=0.04). Control patients were of similar age (32±13 years), sex (5 men, 8 women), and race (all blacks). As would be expected and detailed in Table 2 , not all patients had data available for all portions of the study because of poor intravenous access, patient preference, and inadequate data quality.
Results
Study Populations
CMR Assessment
When compared with controls, the SCD cohort demonstrated severe biatrial dilation, severe biventricular end-diastolic and end-systolic dilation, and LV hypertrophy ( Table 3) independent of SCD genotype, that is, in a pure hemoglobin SS Applanation tonometry 10 25
LGE indicates late gadolinium enhancement; SCD, sickle cell disease; and TTE, transthoracic echocardiography. cohort, after excluding all patients with SCD who had SC or S/β-thal genotypes. LVEF and right ventricular EF were not significantly different in subjects with SCD compared with healthy controls. Only 1 individual with SCD (S/β-thal and none in the control group) had evidence of abnormal myocardial iron content based on T2* assessment. In fact, there was no difference in mean myocardial T2* time between the SCD cohort and the control group. In contrast, half (19/38 patients with SCD vs 0/13 control patients) of the SCD cohort (Table 3 ) exhibited abnormal hepatic T2*. The SCD cohort had significantly lower hepatic T2* times compared with the control group, which remained significant (P=0.0001) in a pure hemoglobin SS cohort. Furthermore, hepatic T2* times were significantly correlated with hemoglobin levels (r=0.36; P=0.05) underscoring the notion that worsening anemia is correlated with increasing burden of blood transfusions and subsequent, increased hepatic iron content. In fact, hepatic T2* values demonstrated an inverse and moderate correlation (r=0.4; P=0.04) with a history of lifetime transfusion burden, partly explaining increased hepatic iron content. These findings were also present in a pure hemoglobin SS cohort (r=0.35; P=0.05). Myocardial perfusion reserve index was significantly lower in patients with SCD than in healthy controls (Table 3) . A quarter of individuals with SCD had evidence of LGE (8 of 32 patients; Figure 1 ). No healthy subjects had LGE (P=0.0826). LGE patterns were noninfarction, focal, and localized in various myocardial regions including inferior, anterolateral, apical, or lateral walls.
Echocardiogram Assessment
SCD subjects had more evidence for diastolic dysfunction (10 of 35) than their control counterparts (1 of 13). All SCD individuals with diastolic dysfunction exhibited grade I or II diastolic dysfunction. Estimated filling pressures (lateral E/e′) were also elevated in patients with SCD with diastolic dysfunction when compared with SCD subjects without diastolic dysfunction (average E/e′ median values [interquartile range], 10.2 [8.8-11 .5] vs 6.9 [5.7-8.0]; P=0.0023] and against healthy controls (7.2 [5.9-9.8] vs 6.0 [5.1-6.7; P=0.0288; Table 3 ). These findings remained significant in a pure hemoglobin SS cohort as well (P=0.01; septal E/e′ values).
Applanation Tonometry
Although systemic systolic or diastolic blood pressures were not different between groups, central aortic distensibility was different in individuals with SCD compared with healthy controls as implied by the AI. Augmentation pressure and AI trended to be higher in SCD subjects. Within SCD subjects, augmentation pressure and AI were significantly correlated with diastolic blood pressure (r=0.68; P<0.0001 and r=0.59; P=0.0015, respectively) and age (r=0.67; P=0.0002 and r=0.61; P=0.0009, respectively) but not correlated with other parameters (r<0.3 and P>0.05 for hemoglobin level, creatinine, CMR myocardial perfusion reserve index, CMR-derived LVEF and LV indexed diastolic volumes, and T2*).
In post hoc subgroup analyses, all but one of the patients with SCD who demonstrated LGE carried a SS genotype, the remaining individual carried a S/β-thal genotype. As shown in Table 4 , patients with SCD and LGE demonstrated significantly increased indexed LA volume, biventricular end-diastolic volumes, increased indexed LV mass, and lower hepatic T2* values. In addition, most patients with LGE did not have evidence of diastolic dysfunction on echocardiography or evidence of abnormal aortic distensibility. After eliminating all patients with SCD with nonhemoglobin SS genotypes, the association of indexed LV mass with LGE remained statistically significant (P=0.0462), whereas the association between the presence of LGE and hepatic T2* values trended near significance (p=0.08) in patients with SS genotype. Finally, during the study period, 2 of 8 (25%) patients with LGE died, whereas no deaths occurred in the 24 patients without LGE. All 6 of the patients who did not have LGE imaging performed were alive at the end of the study period.
When dichotomized by the presence or absence of diastolic dysfunction on TTE ( Table 5 , post hoc), patients with SCD did not differ in any of the chamber volume or mass parameters, the presence of LGE, or by T2* values. However, patients with SCD and diastolic dysfunction had significantly higher augmentation pressure and AI and relatively higher systemic diastolic blood pressures. This association was further reinforced LGE, late gadolinium enhancement; LVEDVi, indexed left ventricular end-diastolic volume; LV, left ventricular; LVEF, left ventricular ejection fraction; LVESVi, indexed left ventricular end-systolic volume; MPRi, myocardial perfusion reserve index; RAi, indexed right atrial volume; RVEDVi, indexed right ventricular end-diastolic volume; RVEF, right ventricular ejection fraction; and RVESVi, indexed right ventricular end-systolic volume. by the correlation between both augmentation pressure and AI with estimated filling pressures on TTE in patients with SCD ( Figure 2 ).
Discussion
Several reports have established that cardiovascular pathology represents the top 3 causes of early mortality in individuals with SCD. The current understanding of these cardiovascular manifestations, however, remains significantly limited. In this study, we show that sickle cell cardiomyopathy is characterized by severe 4-chamber dilation with a significant subset of patients demonstrating diastolic dysfunction, reduced myocardial perfusion reserve suggesting microvascular dysfunction, and, rarely, myocardial iron overload. In addition, in our cohort, myocardial fibrosis was present in 25% of individuals with SCD and was associated with biventricular dilation and hepatic iron overload. We also found that diastolic dysfunction was predominantly associated with increased aortic stiffness and may not be because of a primary myocardial abnormality.
Patients with SCD, despite maintaining normal biventricular EF, demonstrated severe 4-chamber cardiac dilation, presumably because of compensatory myocardial remodeling that occurs in response to chronic anemia. As shown by others, diastolic dysfunction was over-represented in the SCD cohort compared with controls. 1, 9 Diastolic dysfunction is known to be associated with older age, increased blood pressure, and higher creatinine levels in SCD, 1 of which the former 2 characteristics are also observed in our cohort. Although TTE studies, in the past, have shown an association between diastolic dysfunction and increased LV mass, 1 this finding was not confirmed by the CMR evaluation in this cohort. This discrepancy may be explained, in part, because of the improved resolution and accurate quantitative morphological cardiac assessment of CMR compared with conventional echo. In addition to higher diastolic blood pressure, patients with SCD and diastolic dysfunction had evidence of central aortic stiffness, as suggested by differences in AI. When combined, these data suggest that the diastolic dysfunction seen in patients with SCD may be because of increased afterload rather than a direct myocardial pathologic process.
Direct myocardial pathologic processes, including myocardial fibrosis, microvascular disease, and iron deposition, have been postulated as pathogenesis for diastolic dysfunction. This study, however, confirms the lack of significant myocardial iron deposition as measured by myocardial T2* values on CMR. In addition, vasodilator perfusion imaging does not reveal an association between diastolic dysfunction and myocardial perfusion reserve index, a surrogate for microvascular dysfunction. Patients with diastolic dysfunction also did not have a higher incidence of LGE. These findings begin to link the observations of poor outcomes with diastolic dysfunction with the presence of relative hypertension in SCD, a concept described by the presence of normal systemic blood pressures that do not protect patients with SCD from the risk of arterial stiffness and development of diastolic dysfunction.
The presence of LGE has been reported rarely in previous studies evaluating smaller cohorts and case reports of patients with SCD. [12] [13] [14] [15] [16] Notably, the significant proportion of patients with LGE is a novel finding in patients with SCD. In the current cohort, the LGE pattern is best characterized as small, focal, and mid-wall in a distribution that would be highly atypical for myocardial infarction related to epicardial coronary artery disease. Potential explanations for the presence of LGE may include microvascular ischemic complications or a history of myocardial infarction. The presence of LGE, however, was shown not to be associated with abnormal myocardial perfusion reserve, and an myocardial infarction is a rare occurrence in SCD, as documented previously by case reports, 17 in contrast to a significant proportion of patients with LGE in our cohort. The presence of LGE, however, was correlated with significant LV dilation and decreased hepatic T2* values, which were also associated with increased lifetime transfusion burden. These findings suggest that LGE is associated with increasing severity of anemia and SCD.
To date, autopsy evidence with regard to the presence of myocardial fibrosis in individuals with SCD has been controversial. [18] [19] [20] [21] Although we did not have tissue samples available from any of the patients in this cohort, we were able to confirm the histologic presence of myocardial fibrosis in 6 available autopsy SCD myocardial specimens obtained from patients with a history of preserved LVEF who were not enrolled in this study. As shown in Figure 3 , patients with SCD can have ≥3 different patterns of myocardial fibrosis: (1) a low-grade diffuse myocardial fibrosis pattern; (2) severe and transmural fibrosis pattern; or (3) a mild and patchy pattern. The autopsy tissue analysis suggests that the underlying explanation of LGE seen in our cohort may indeed be myocardial fibrosis. The specific pathophysiology and significance of LGE and myocardial fibrosis in SCD, however, remain unknown. As mentioned above, the presence of LGE does not seem to be linked to diastolic LV impairment in this cohort. Interestingly, sudden death has been reported in SCD as one of the top causes of mortality; in the current cohort, 2 deaths were reported during the duration of the study (3 years), both of whom had evidence of LGE on CMR. Whether this outcome was because of ventricular arrhythmias caused by myocardial scar is unknown and requires further investigation.
Although the majority represented those with a SS background, this study also included a mixture of other patient genotypes, including 4 SC and 4 S/β-thal patients. All of the analyses were performed initially as a unified and mixed cohort and, subsequently, in the group with only SS genotype. Importantly, nearly all of the predominant findings from this study remained significant after excluding non-SS genotypes. In fact, when compared with healthy nonsickle controls, majority of the indices of severity of SCD in patients with the SS genotype all trended with greater statistical significance once these other non-SS genotypes were excluded including increased 4-chamber dilation, increased transfusion burden, decreased hepatic 2* times, increased echo-derived filling pressures, and decreased hemoglobin levels.
Limitations
This study has several limitations. Although this cohort represents a small sample size at a single institution all in steadystate condition, this study represents the largest prospective cohort of SCD to undergo a same day comprehensive CMR protocol along with other noninvasive cardiovascular tests, including tonometry and echocardiography. Nonetheless, caution should be considered in applying these results to all patients with SCD, in particular to those with genotypes outside of hemoglobin SS (given the vast majority with SS in this current study) and those with a recent or ongoing crisis. Not all patients had evaluable data sets for all of the cardiovascular tests, predominantly because of reasons such as inadequate venous access, frequently encountered in patients with SCD. Finally, our follow-up period is currently too short to make meaningful comments on outcomes such as mortality and functional status.
Conclusions
Sickle cell cardiomyopathy is characterized by 4-chamber dilation, preserved systolic function, microvascular dysfunction, and abnormal diastolic function associated with increased central aortic stiffness and afterload. In addition, in our cohort of patients, myocardial fibrosis is a relatively common complication of SCD, which occurs more often in patients who have evidence of hepatic iron overload and LV dilation. Finally, myocardial iron overload is a rare complication of SCD.
